Neurobiological similarities in depression and drug dependence: A self-medication hypothesis

Neuropsychopharmacology

Volumn 18, Issue 3, 1998, Pages 135-174

  Markou, Athina ^a   Kosten, Thomas R ^b   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Comorbidity; Corticotropin releasing factor; Depression; Dopamine; Drug dependence; Ethanol; Gamma aminobutyric acid; Motivation; Neuropeptide Y; Norepinephrine; Opiate; Psychomotor stimulant; Review; Self medication; Serotonin; Somatostatin

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ALCOHOL; ALPRAZOLAM; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; AUTORECEPTOR; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; COCAINE; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DOPAMINE; FLUOXETINE; MIANSERIN; NEUROPEPTIDE Y; NEUROTRANSMITTER; NICOTINE; NISOXETINE; NORADRENALIN; OPIATE; OPIATE RECEPTOR; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN; UNINDEXED DRUG;

COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG WITHDRAWAL; HUMAN; NEUROBIOLOGY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SELF MEDICATION; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; COMORBIDITY; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; NEUROPEPTIDE Y; NOREPINEPHRINE; SEROTONIN; SUBSTANCE-RELATED DISORDERS;

EID: 0032031305     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00113-9     Document Type: Review

References (466)

1. Acquas E, Carboni E, DiChiara G (1991): Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. Eur J Pharmacol 193:133-134
2. Acquas E, DiChiara G (1992): Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem 58:1620-1625
3. Aghajanian GK (1978): Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine, Nature 276:186-188
4. Agren H, Lundqvist G (1984): Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 9:233-248
5. 1A recep-tor gene. J Biol Chem 265(10):5825-5832
6. American Psychiatric Association (1994): Diagnostic and Statistical Manual of Mental Disorders IV. Washington DC, American Psychiatric Association
7. Andersson K, Fuxe K, Eneroth P, Jansson A, Harfstrand A (1989): Effects of withdrawal from chronic exposure to cigarette smoke on hypothalamic and preoptic catecholamine nerve terminal systems and on the secretion of pituitary hormones in the male rat. Naunyn-Schmiedebergs Arch Pharmacol 339:387-396
8. Andrews N, File SE (1993): Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: A review of supporting neurochemical and behavioural evidence. Psychopharmacology 112:21-25
9. Anisman H, Zacharko RM (1982): Depression: The predisposing influence of stress. Behav Brain Sci 5:101-102
10. 2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 47:1038-1047
11. Arato M, Banki CM, Bissette G, Nemeroff CB (1989): Elevated CSF CRF in suicide victims. Biol Psychiatry 25: 355-259
12. Aronson SC, Black JE, McDougle CJ, Scanley BE, Jatlow P, Kosten TR, Heninger GR, Price LH (1995): Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology 119:179-185
13. 2 binding sites in the frontal cortex of suicide victims of control subjects. Am J Psychiatry 146:730-736
14. Artigas F, Perez V, Alvarez E (1994): Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 248-251
15. Asakura M, Tsukamoto T, Kubota H, Imafuku J, Ino M, Nishizaki J, Sato A, Shinbo K, Hasegawa K (1987): Role of serotonin in the regulation of beta-adrenoceptors by antidepressants. Eur J Pharmacol 141:95-100
16. Asberg M, Bertilsson L, Martensson B, Scalia-Tomba GP, Thoren P, Traskman-Bendz L (1984): CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 69: 201-219
17. Asberg M, Ringberger VA, Sjoqvist F, Thoren P, Traskman L, Tuck JR (1975): Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin Pharmacol Ther 21:201-207
18. Asberg M, Traskman L, Thoren P (1976): 5-HIAA in the cerebrospinal fluid: A biochemical suicide predictor? Arch Gen Psychiatry 33:1193-1197
19. Atterwill CK (1980): Lack of effect of repeated electroconvulsive shock on [3H] spiroperidol and [3H] 5-hydroxytryptamine binding and cholinergic parameters in rat brain. J Neurochern 35:729-734
20. Aubin HJ, Tilikete S, Barrucand D (1996): Depression and smoking. Encephale 22(1):17-22
21. Auerbach SB, Hjorth S (1995): Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn-Schmiedebergs Arch Pharmacol 352:597-606
22. Axelrod J, Kopin IJ, Mann JD (1959): 3-Methoxy-4-hydroxyphenylglycol sulfate, a new metabolite of epinephrine and norepinephrine. Biochim Biophys Acta 36:576-577
23. Balakleevsky A, Colombo G, Fadda F, Gessa GL (1990): Ro 19-4603, a benzodiazepine receptor inverse agonist, attentuates voluntary ethanol consumption in rats selectively bred for high ethanol preference. Alcohol Alcohol 25: 449-452
24. Banerjee SP, Kung LS, Riggi SJ, Chanda SK (1977): Development of beta-adrenergic receptor subsensitivity by antidepressants. Nature 268:455-456
25. Banki CM, Karmacsi L, Bissette G, Nemeroff CB (1992): CSF corticotropin-releasing hormone and somatostatin in major depression: Response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 2:107-113
26. Barkai A, Durkin M, Nelson HD (1990): Localized alterations of dopamine receptor binding in rat brain by repeated electroconvulsive shock: An autoradiographic study. Brain Res 529:208-213
27. Baron BM, Ogden A-M, Siegel BW, Stegeman J, Ursillo RC, Dudley MW (1988): Rapid downregulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 154:125-134
28. Batki SL (1988): Treatment of intravenous drug users with AIDS: The role of methadone maintenance. J Psychoactive Drugs 20:213-216
29. Beasley CM, Masica DN, Potvin JH (1992): Fluoxetine: A review of receptor and functional effects and their clinical implications. Psychopharmacology 107(1 ):1-10
30. Bel N, Artigas F (1993): Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243-245
31. Bel N, Artigas F (1996): In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function: Microdialysis studies. J Pharmacol Exp Ther 278(3):1064-1072
32. Bellman R, Sperk G (1993): Effects of antidepressant drug treatment on levels of NPY or prepro-NPY-mRNA in the rat brain. Neurochem Int 22:183-187
33. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN (1994): Mood-lowering effect of tryptophan depletion: Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psych 51:687-697
34. Benloucif S, Kegan MJ, Galloway MP (1993): Serotonin-facilitated dopamine release in vivo: Pharmacological characterization. J Pharmacol Exp Ther 265:373-377
35. Bergstrom DA, Kellar KJ (1979): Effect of electroconvulsive shock on monoaminergic receptor binding sites in rat brain. Nature 278:464-466
36. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS (1997): Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A doubleblind, placebo-controlled trial. Am J Psychiatry 154(1):37-43
37. Berrettini WH, Doran AR, Kelsoe J, Roy A, Pickar D (1987): Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. Neuropsychopharmacology 1:81-83
38. Biegon A, Israeli M (1988): Regionally selective increases in beta-adremergic receptor density in the brains of suicide victims. Brain Res 442:199-203
39. Blackshear MA, Sanders-Bush E (1982): Serotonin-receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221:303-308
40. Blier P, Bergeron R (1995): Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15(3):217-222
41. 1A receptors induces rapid antidepressant response. Neuropsychopharmacology 16(5):333-338
42. Blier P, Chaput Y, de Montigny C (1988): Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: An electrophysiological study in the rat brain. Naunyn-Schmiedebergs Arch Pharmacol 337:246-254
43. 1A agonist gepirone: Electrophysiological studies in the rat brain. Synapse 1:470-480
44. Blier P, de Montigny C (1990): Differential effect of gepirone on presynaptic and postsynaptic serotonin receptors: Single-cell recording studies. J Clin Psychopharmacol 10(Suppl 3):13S-20S
45. Blier P, de Montigny C (1994): Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226
46. Blier P, de Montigny C, Chaput Y (1990): A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. J Clin Psychiatry 51(Suppl 4):14-20
47. Bokstrom K, Balldin J (1992): A rating scale for assessment of alcohol withdrawal psychopathology (AWIP). Alcohol Clin Exp Res 16:241-249
48. A receptors are present on noradrenergic nerve terminals in selective areas of the rat brain. Synapse 1:254-257
49. 1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacology 117:358-363
50. Boulenger JP, Lavallee YJ (1993): Mixed anxiety and depression: Diagnostic issues. J Clin Psychiatry 54(Suppl 1):3-8
51. Bozarth MA, Wise RA (1981): Intracranial self-administration of morphine into the ventral tegmental area in rats. Life Sci 28:551-555
52. Breslau N, Davis GC (1986): Chronic stress and major depression. Arch Gen Psychiatry 43:309-314
53. Breslau N, Kilbey M, Andreski P (1993): Nicotine dependence and major depression: New evidence from a prospective investigation. Arch Gen Psychiatry 50:31-35
54. Brown SA, Schuckit MA (1988): Changes in depression among abstinent alcoholics. J Stud Alcohol 49(5):412-417
55. Bryant KJ, Rounsaville B, Spitzer RL, Williams JB (1992): Reliability of dual diagnosis: Substance dependence and psychiatric disorders. J Nerv Mental Dis 180:251-257
56. Bunney WE, Davis JM (1965): Norepinephrine in depressive reactions: A review. Arch Gen Psychiatry 13:483-494
57. 2A receptor expression. Neuroreport 6:901-904
58. Busto UE, Sellers EM (1991): Anxiolytics and sedative/hypnotics dependence. Br J Addition 86:1647-1652
59. Byerley WF, McConnell EJ, MaCabe RT, Dawson TM, Grosser BI, Wamsley JK (1987): Chronic administration of sertraline, a selective serotonin uptake inhibitor, decreased the density of beta-adrenergic receptors in rat frontoparietal cortex. Brain Res 421(1-2):377-381
60. Caine SB, Heinrichs SC, Coffin VL, Koob GF (1995): Effects of the dopamine, D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res 692:47-56
61. Caldecott-Hazard S, Morgan DG, DeLeon-Jones M, Overstreet DH, Janowsky D (1991): Clinical and biochemical aspects of depressive disorders. II. Transmitter/receptor theories. Synapse 9:251-301
62. Caldecott-Hazard S, Schneider LS (1992): Clinical and biochemical aspects of depressive disorders: III. Treatment and controversies. Synapse 10:141-168
63. Carboni E, Acquas E, Leone P, DiChiara G (1989): 5HT3 receptor antagonists block morphine-and nicotine-but not amphetamine-induced reward. Psychopharmacology 97:175-178
64. Carroll ME, Lac ST, Ascencio M, Kragh R (1990): Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 35:237-244
65. Chaput Y, de Montigny C, Blier P (1986): Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain. Naunyn-Schmiedebergs Arch Pharmacol 333:342-348
66. Chaput Y, de Montigny C, Blier P (1991): Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5(4):219-229
67. Charney DS, Menkes DB, Heninger GR (1981): Receptor sensitivity and the mechanism of action of antidepressant treatment: Implications for the etiology and therapy of depression. Arch Gen Psychiatry 38:1160-1180
68. A/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res 460:114-123
69. Chen NH, Reith ME (1994a): Autoregulation and monoamine interactions in the ventral tegmental area in the absence and presence of cocaine: A microdialysis study in freely moving rats. J Pharmacol Exp Ther 271(3): 1597-1610
70. Chen NH, Reith ME (1994b): Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: A microdialysis study on monoamine interrelationships. J Neurochem 63(5):1701-1713
71. Ciraulo DA, Jaffe JH (1981): Tricyclic antidepressants in the treatment of depression associated with alcoholism. J Clin Psychopharmacol 1:146-150
72. Clarke PBS, Pert A (1985): Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348:355-358
73. Cohen RM, Campbell IC, Dauphin M, Tallman JF, Murphy DL (1982): Changes in alpha-and beta-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. Neuropharmacology 21:293-298
74. Copp JE, Schwiderski UE, Robinson DS (1990): Symptom comorbidity in anxiety and depressive disorders. J Clin Psychopharmacol 10 (Suppl 3):52S-60S
75. Coppen A (1967): The biochemistry of affective disorders. Br J Psychiatry 113:1237-1264
76. Coppen AJ, Doogan DP (1988): Serotonin and its place in the pathogenesis of depression. J Clin Psychiatry 49 (Suppl 8): 4-11
77. Cornelius JR, Salloum IM, Cornelius MD, Perel JM, Ehler JG, Jarrett PJ, Levin RL, Black A, Mann JJ (1995): Preliminary report: Double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull 31(2):297-303
78. Cornell DG, Milden RS, Shimp S (1985): Stressful life events associated with endogenous depression. J Nerv Ment Dis 173:470-476
79. Covey LS, Glassman AH, Stetner F (1990): Depression and depressive symptoms in smoking cessation. Compr Psychiatry 31(4):350-354
80. Covey LS, Hughes DC, Glassman AH, Blazer DG, George LK (1994): Ever-smoking, quitting, and psychiatric disorders: Evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tob Control 3:222-227
81. 1A receptor sensitivity in major depression: A neuroendocrine study with buspirone. Br J Psychiatry 164:372-379
82. Crews FT, Paul SM, Goodwin FK (1981): Acceleration of beta-receptor desensitization in combined administration of antidepressants and phenoxybenzamine. Nature 290:787-789
83. Cropper M, Garner A, McEwan GD, Munt DF, Rushbrook LA, Stevens V, Baker AC (1987): A double-blind comparative study of alprazolam and diothiepin hydrochloride in the treatment of anxiety associated with depression. Pharmatherapeutica 5(2):76-82
84. B receptors consistent findings following chronic antidepressant administration? Eur J Pharmacol 141:159-162
85. Cummings JL (1985): Psychosomatic aspects of movement disorders. Adv Psychosom Med 13:111-132
86. Dahlstrom A, Fuxe K (1964): Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brainstem neurons. Acta Physiol Scand Suppl 232:1-55
87. Dalack GW, Glassman AH, Rivelli S, Covey L, Stetner F (1995): Mood, major depression, and fluoxetine response in cigarette smoking. Am J Psychiatry 152(3):398-403
88. Dani JA, Heinemann S (1996): Molecular and cellular aspects of nicotine abuse. Neuron 16(5):905-908
89. Davis JM, Koslow SH, Gibbons RD, Maas JW, Bowden CL, Casper R, Hanin I, Javaid JI, Chang SS, Stokes PE (1988): Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls. Arch Gen Psychiatry 45:705-717
90. Davis WM, Smith TE, Smith SG (1987): Intravenous and intragastric self-administration of chlordiazepoxide in the rat. Alcohol Drug Res 7:511-516
91. DeBellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA (1993): Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone with arginine vasopressin in patients with major depression. Am J Psychiatry 150:656-657
92. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990): Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psych 47:411-418
93. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, Charney DS (1993): Monoamines and the mechanism of antidepressant action: Effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 29(3):389-396
94. Delgado PL, Price LH, Miller LH, Salomon RM, Aghajanian GK, Heninger GR, Charney DS (1994): Serotonin and the neurobiology of depression: Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psych 51:865-874
95. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH, Heninger GR, Charney DS (1991): Rapid serotonin depletion as a provocative challenge test for patients with major depression: Relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 27(3):321-330
96. de Montigny C, Aghajanian GK (1978): Tricyclic antidepressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202:1303-1306
97. De Montis GM, Devoto P, Gessa GL, Meloni D, Porcella A, Saba P, Serra G, Tagliamonte A (1990): Central dopaminergic transmission is selectively increased in the limbic system of rats chronically exposed to antidepressants. Eur J Pharmacol 180:31-35
98. De Paermentier F, Cheetham SC, Crompton MR, Katona CLE, Horton RW (1990): Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res 525:71-77
99. deWit H, Wise RA (1977): Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine and phenoxybenzamine. Can J Psychol 31:195-203
100. Dilsaver SC (1986): Cholinergic mechanisms in depression. Brain Res 396:285-316
101. 1A receptors. Neurochem Res 21:557-562
102. Edwards G (1990): Withdrawal symptoms and alcohol dependence: Fruitful mysteries. Br J Addiction 85:447-461
103. 2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol 11:389-392
104. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C (1996): Mood response to acute tryptophan depletion in healthy volunteers: Sex differences and temporal stability, Neuropsychopharmacology 15(5):465-474
105. 1B binding sites. Naunyn-Schmiedebergs Arch Pharmacol 332:1-7
106. 1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J Neurochem 66:599-603
107. Epping-Jordan MP, Markou A, Koob GF (1997) The dopamine D-1 receptor antagonist SCH 23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat. Brain Research. In press.
108. Esposito E, Kruszewska A, Ossowska G, Samanin R (1987): Noradrenergic and behavioural effects of naloxone injected into the locus coeruleus of morphine-dependent rats and their control by clonidine. Psychopharmacology 93:393-396
109. Falk JL, Tang M (1989): Schedule-induction of drug intake: Differential responsiveness to agents with abuse potential. J Pharmacol Exp Ther 249(1):143-148
110. Ferrer A, Artigas F (1994): Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain. Eur J Pharmacol 263:227-234
111. Ferry LH, Burchette RJ (1994): Evaluation of buproprion versus Placebo for treatment of nicotine dependence. American Psychiatry Association New Research, Washington, DC, pp. 199-200
112. Fibiger HC (1991): The dopamine hypotheses of schizophrenia and mood disorders: Contradictions and speculations. In Willner P, Schell-Kruger J (eds), The Mesolimbic Dopamine System: From Motivation to Action. Chichester, U.K., John Wiley and Sons, pp 615-637
113. Florin SM, Kuczenski R, Segal DS (1994): Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res 654(1):53-62
114. Florin SM, Kuczenski R, Segal DS (1995): Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: Mechanistic and behavioral considerations. J Pharmacol Exp Ther 274(1):231-241
115. Foote SL, Bloom Fe, Aston-Jones G (1983): Nucleus locus ceruleus: New evidence of anatomical and physiological specificity. Physiol Rev 63(3):844-914
116. France RD, Urban B, Krishnan KRR, Bissett G, Banki CM, Nemeroff C, Speilman FJ (1988): CSF corticotropin-releasing factor-like immunoreactivity in chronic pain patients with and without major depression. Biol Psychiatry 23:86-88
117. Frazer A, Hess ME, Mendels J, Gable B, Kunkel E, Bender A (1978): Influence of acute and chronic treatment with desmethylimipramine on catecholarnine effects in the rat. J Pharmacol Exp Ther 206:311-319
118. Fujiwara Y, Nelson DL, Kashihara K, Varga E, Roeske WR, Yamamura HI (1990): The cloning and sequence analysis of the rat serotonin-1A receptor gene. Life Sci 47: PL127-PL132
119. Fuller RW, Wong DT (1987): Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol 7(Suppl 6): 36S-43S
120. Fuxe K, Ogren S-O, Agnati LF, Benfenati F, Fredholm B, Andersson K, Zini I, Eneroth P (1983): Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology 22(3B):389-400
121. 1A autoreceptors in the mechanism of action of serotonergic antidepressant drugs: Recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 10:16-27
122. Gawin FH, Kleber HD (1986): Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch Gen Psychiatry 43:107-113
123. Gerner RH, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M, Hare TA, Shaywitz BA, and Cohen DJ (1984): CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry 141:1533-1540
124. Gerner RH, Yamada T (1982): Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 238:298-302
125. Geyer MA, Markou A (1995): Animal models of psychiatric disorders. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 787-798
126. Gheorvassaki EG, Thermos K, Liapakis G, Spyraki C (1992): Effects of acute and chronic desipramine treatment on somatostatin receptors in brain. Psychopharmacology 108:363-366
127. Gillin JC (1982): Sleep studies in affective illness: Diagnostic, therapeutic, and pathophysiological implications. Psychiatry Annuals 13:367-384
128. Gillin JC, Pulvirenti L, Withers N, Golshan S, Koob G (1994): The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report. Biol Psychiatry 35:843-849
129. Gjerris A, Widerlov E, Werdelin L, Ekman R (1992): Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls. J Psychiatry Neurosci 17(1):23-27
130. Glassman AH (1993): Cigarette smoking: Implications for psychiatric illness. Am J Psychiatry 150(4):546-553
131. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, Johnson J (1990): Smoking, smoking cessation and major depression. J Am Med Assoc 264(12):1546-1549
132. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, Covey LS (1988): Heavy smokers, smoking cessation and clonidine: Results of a double-blind, randomized trial. J Am Med Assoc 259(19):2863-2866
133. Glowinski J, Kopin IJ, Axelrod J (1965): Metabolism of 3H-norepinephrine in the rat brain. J Neurol Chem 12:25-30
134. Goeders NE, Bienvenu OJ, De Souza EB (1990): Chronic cocaine administration alters cortocotropin-releasing factor receptors in the rat brain. Brain Res 531:322-328
135. Goeders NE, Lane JD, Smith JE (1984): Self-administration of methionine enkephalin into the nucleus accumbens. Pharmacol Biochem Behav 20:451-455
136. Goodnough DB, Baker GB (1994): 5-Hydroxtryptamine and beta-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J Neurochem 62(6):2262-2268
137. Goodwin DW (1992): Alcohol: Clinical aspects, In Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds), Substance Abuse: A Comprehensive Textbook. Baltimore, MD, Williams and Wilkins, pp 144-151
138. 2 receptor-mediated head-twitch behaviour following antidepressant treatment in mice. Br J Pharmacol 83:235-242
139. Goodwin FK, Post RM, Dunner DL, Gordon EK (1973): Cerebrospinal fluid amine metabolites in affective illness: The probenecid technique. Am J Psychiatry 130:73-79
140. Grant KA. (1994): Emerging neurochemical concepts in the actions of ethanol at ligand-gated ion channels. Behav Pharmacol 5:383-404
141. Green AR (1987): Evolving concepts on the interactions between antidepressant treatments and monoamine neurotransmitters. Neuropharmacology 26:815-822
142. Green AR, Deakin JFW (1980): Brain noradrenaline depletion prevents ECS-induced enhancement of serotonin- and dopamine-mediated behaviour. Nature 285:232-233
143. 2 receptor number in brain as a probable explanation for the enhanced 5-hydroxytryptamine-mediated behaviour following repeated electroconvulsive shock administration to rats. Br J Pharmacol 80:173-177
144. Greenblatt DJ, Shader RI (1978): Dependence, tolerance, and addiction to benzodiazepines: Clinical and pharmacokinetic considerations. Drug Metab Rev 8:13-28
145. Griffiths RR, Ator NA (1980): Benzodiazepine self-administration in animals and humans: A comprehensive literature review. NIDA Res Monogr 33:22-36
146. Griffiths RR, Bigelow G, Liebson I (1979): Human drug self-administration: Double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J Pharmacol Exp Ther 210:301-310
147. Griffiths RR, Bigelow GE, Liebson I, Kaliszak JE (1980): Drug preference in humans: Double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther 215:649-661
148. Griffiths RR, Lukas SE, Bradford LD, Brady JV, Snell JD (1981): Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology 75:101-109
149. 1A receptors. Mol Pharmacol 41: 695-698
150. Haertzen CA, Hooks NT Jr (1969): Changes in personality and subjective experience associated with the chronic administration and withdrawal of opiates. J Nerv Ment Dis 148:606-614
151. Hammen CL, Cochran SD (1981): Cognitive correlates of life stress and depression in college students. J Abnorm Psychol 90:23-27
152. Harrington R, Fudge H, Rutter M, Pickles A, Hill J (1990): Adult outcomes of childhood and adolescent depression. I. Psychiatric status. Arch Gen Psychiatry 47:465-473
153. 2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 371:155-157
154. Heal DJ, Akagi H, Bowdler JM, Green AR (1981): Repeated electroconvulsive shock attenuates clonidine-induced hypoactivity in rodents. Eur J Pharmacol 75:231-237
155. Heal DJ, Green AR (1978): Repeated electroconvulsive shock increases the behavioural responses of rats to ingestion of both dopamine and dibutyryl cyclic AMP into the nucleus accumbens. Neuropharmacology 17:1085-1087
156. Heal DJ, Lister S, Smith SL, Davies CL, Molyneux SG, Green AR (1983): The effects of acute and repeated administration of various antidepressant drugs on clonidine induced hypoactivity in mice and rats. Neuropharmacology 22:983-992
157. Heilig M, Ekman R (1995): Chronic parenteral antidepressant treatment in rats: Unaltered levels and processing of neuropeptide Y (NPY) and corticotropin-releasing hormone (CRH). Neurochem Int 26(4):351-355
158. Heilig M, Koob GF, Ekman R, Britton KT (1994): Corticotropin-releasing factor and neuropeptide Y: Role in emotional integration. Trends Neurosci 17:80-85
159. Heilig M, McLeod S, Koob GF, Britton KT (1992): Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41:61-69
160. Heilig M, Widerlov E (1990): Neuropeptide Y: An overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr Scand 82:95-114
161. Heimer L, Alheid GF (1991): Piecing together the puzzle of basal forebrain anatomy. In Napier TC, Kalivas PW, Hanin I (eds), The Basal Forebrain: Anatomy to Function. New York, Plenum Press, pp 1-42
162. Heimer L, Alheid GF, Zabaorszky L (1985): The basal ganglia. In Paxinos G (ed), The Rat Nervous System. Sydney, Academic Press, pp 37-74
163. Heimer L, de Olmos J, Alheid GF, Zaborszky L (1991): "Perestroika" in the basal forebrain: Opening the border between neurology and psychiatry. Prog Brain Res 87: 109-165
164. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L (1995): Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 6:74-80
165. Heninger GR, Delgado PL, Charney DS (1996): The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29:2-11
166. Henningfield JE, Johnson RE, Jasinski DR (1987): Clinical procedures for the assessment of abuse potential. In Bozarth MA (ed), Methods of Assessing the Reinforcing Properties of Abused Drugs. New York, Springer-Verlag, pp 573-590
167. Hill Sy, Hruska DR (1992): Childhood psychopathology in families with multigenerational alcoholism. J Am Acad Child Adolesc Psychiatry 31:1024-1030
168. Himmelsbach CK (1943): IV. With reference to physical dependence. Fed Proc 2:201-203
169. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: A microdialysis study. J Neurochem 60:776-779
170. 1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur J Pharmacol 260:251-255
171. 1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology 33:331-334
172. 1A receptors or beta-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo. Eur J Pharmacol 316(1):43-47
173. Honig A, Bartlett JR, Bouras N, Bridges PK (1989): Amino acid levels in depression: A preliminary investigation. J Psychiatr Res 22:159-164
174. Hover D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994): VII, International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203
175. 2 receptors in rat brain: An autoradiography study. Synapse 14:324-331
176. Hughes JR (1993): Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. J Clin Psychiatry 54(3):109-114
177. Hunkeler W, Mohler H, Pieri L, Polc P, Bonetti EP, Cumin R, Schaffner R, Haefely W (1981): Selective antagonists of benzodiazepines. Nature 290:514-516
178. Hyttel J, Overo KF, Arnt J (1984): Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology 83:20-27
179. A antagonism in the extended amygdala decreases ethanol self-administration in rats. Eur J Pharmacol 283:151-159
180. Imperato A, Mele A, Scrocco MG, Puglisi-Allegra S (1992): Chronic cocaine alters extracellular dopamine: Neurochemical basis for addiction. Eur J Pharmacol 212:299-300
181. Idemudia SO, Bhadra S, Lal H (1989): The pentylenetetrazol-like interoceptive stimulus produced by ethanol withdrawal is potentiated by bicuculline and picrotoxinin. Neuropsychopharmacology 2:115-122
182. Ingraham LJ, Wender PH (1992): Risk for affective disorder and alcohol and other drug abuse in the relatives of affectively ill adoptees. J Affect Disord 26:45-51
183. 1A receptors. Eur J Pharmacol 260:243-246
184. Jaffe JH (1990): Drug addiction and drug abuse. In Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds), The Pharmacological Basis of Therapeutics, 8th ed. Elmsford, New York, Pergamon Press, pp 522-573
185. Janowsky DS, El-Yousef MK, Davis JM (1974): Acetylcholine and depression. Psychosom Med 36:248-257
186. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1972): A cholinergic-adrenergic hypothesis of mania and depression. Lancet 2:632-635
187. Janowsky A, Okada F, Manier D, Applegate C, Sulser F (1982): Role of serotonergic input in the regulation of the beta-adrenergic receptor-coupled adenylate cyclase system. Science 218:900-901
188. Janowsky A, Overstreet DH (1995): The role of acetylcholine mechanisms in mood disorders. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 945-956
189. Janowsky DS, Risch SC, Parker D, Huey LY, Judd LL (1980): Increased vulnerability to cholinergic stimulation in affective-disorder patients. Psychopharmacol Bull 16: 29-31
190. Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME, Reich LA (1990): Gepirone in the treatment of major depression. J Clin Psychopharmacol 10(Suppl 3):77S-85S
191. 2-and beta-adrenoceptor sensitivity. Eur J Pharmacol 67:123-127
192. Jonzon B, Fredholm BB (1984): Adenosine mechanisms are not affected by antidepressant concentrations of desipramine. J Pharm Pharmacol 36:846-848
193. Juergens SM (1993): Benzodiazepines and addiction. Psychiatr Clin North Am 16:75-86
194. June HL, Hughes RW, Spurlock HL, Lewis MJ (1994a): Ethanol self-administration in freely feeding and drinking rats: Effects of RO15-4513 alone, and in combination with RO15-1788 (flumazenil). Psychopharmacology 115:332-339
195. June HL, Lummis GH, Colker RE, Moore TO, Lewis MJ (1991): RO 15-4513 attenuates the consumption of ethanol in deprived rats. Alcohol Clin Exp Res 15:406-411
196. June HL, Murphy JM, Mellor-Burke JJ, Lumeng L, Li TK (1994b): The benzodiazepine inverse agonist RO19-4603 exerts prolonged and selective suppression of ethanol intake in alcohol-preferring (P) rats. Psychopharmacology 115:325-331
197. Kakigi T, Maeda K, Kaneda H, Chihara K (1992): Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain. J Affect Disord 25:215-220
198. Kanner AD, Coyne JC, Schaefer C, Lazarus RS (1981): Comparison of two models of stress measurement: Daily hassles and uplifts versus major life events. J Behav Med 4:1-39
199. Kapur S, Mann JJ (1992): Role of the dopaminergic system in depression. Biol Psychiatry 32:1-17
200. Kellar KJ, Cascio CS, Butler JA, Kurtzke RN (1981): Differential effects of electroconvulsive shock and antidepressant drugs on serotonin-2 receptors in rat brain. Eur J Pharmacol 69:515-518
201. Kendler KS, Heath AC, Neale MC, Kessler RC, Eaves LJ (1993a): Alcoholism and major depression in women: A twin study of the causes of comorbidity. Arch Gen Psychiatry 50(9):690-698
202. Kendler KS, Kessler RC, Walters EE, MacLean C, Neale MC, Heath AC, Eaves LJ (1995a): Stressful life events, genetic liability, and onset of an episode of major depression in women. Am J Psychiatry 152:833-842
203. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC (1993b): Smoking and major depression: A causal analysis. Arch Gen Psychiatry 50:36-43
204. Kendler KS, Walters EE, Neale MC, Kessler RC, Heath AC, Eaves LJ (1995b): The structure of the genetic and environmental risk factors for six major psychiatric disorders in women: Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry 52:374-383
205. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994): Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19
206. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ (1996): The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization. Am J Orthopsychiatry 66(1):17-31
207. Kleber HD, Weissman MM, Rounsaville BJ, Wilber CH, Prusoff BA, Riordan CE (1983): Imipramine as treatment for depression in addicts. Arch Gen Psychiatry 40(6):649-653
208. Kleven MS, Woolverton WL (1993): Effect of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug Alcohol Depend 31(2):149-158
209. Klimek V, Maj J (1989): Repeated administration of antidepressants enhances agonist affinity for mesolimbic D2-receptors. J Pharm Pharmacol 41:355-558
210. 3H-SCH 23390 binding sites in the rate striatum and limbic system. Eur J Pharmacol 139:163-169
211. 3H]-pilflutixol binding sites in the rate striatum. Eur J Pharmacol 109:131-132
212. Kling MA, Rubinow DR, Doran AR, Roy A, Davis CL, Calabrese JR, Nieman LK, Post RM, Chrousos GP, Gold PW (1993): Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's Disease and major depression: Relationship to indices of corticotropin-releasing hormone and cortisol secretion. Neuroendocrinology 57:79-88
213. Knop J, Goodwin DW, Jensen P, Penick E, Pollock V, Gabrielli W, Teasdael TW, Mednick SA (1993): A 30-year follow-up study of the sons of alcoholic men. Acta Psychiatr Scand 370:48-53
214. Koe BK, Koch SW, Lebel LA, Minor KW, Page MG (1987): Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of beta-adrenoceptor system of rat brain. Eur J Pharmacol 141:187-194
215. Koob GF, Bloom FE (1988): Cellular and molecular mechanisms of drug dependence. Science 242:715-723
216. Koob GF, Caine B, Markou A, Pulvirenti L, Weiss F (1994a): Role for the mesocortical dopamine system in the motivating effects of cocaine. NIDA Res Monogr 145:1-18
217. Koob GF, Goeders NE (1989): Neuroanatomical substrates of drug self-administration. In Liebman JM, Cooper SJ (eds), The Neuropharmacological Basis of Reward. New York, Oxford University Press, pp 214-263
218. Koob GF, Heinrichs SC, Menzaghi F, Merlo Pich E, Britton KT (1994b): Corticotropin releasing factor, stress and behavior. Semin Neurosci 6:221-229
219. Koob GF, Maldonado R, Stinus L (1992): Neural substrates of opiate withdrawal. Trends Neurosci 15:186-191
220. Koob GF, Markou A, Weiss F, Schulteis G (1993): Opponent process and drug dependence: Neurobiological mechanisms. Semin Neurosci 5:351-358
221. Koob GF, Stinus L, LeMoal M, Bloom FE (1989a): Opponent process theory of motivation: Neurobiological evidence from studies of opiate withdrawal. Neurosci Biobehav Rev 13:135-140
222. Koob GF, Wall TL, Bloom FE (1989b): Nucleus accumbens as a substrate for the aversive stimulus effects of opiate withdrawal. Psychopharmacology 98:530-534
223. Koob GF, Weiss F (1992): Neuropharmacology of cocaine and ethanol dependence. In Galanter M (ed), Recent Developments in Alcoholism, Volume 10: Alcohol and Cocaine: Similarities and Differences. New York, Plenum Press, pp 201-233
224. Koslow SH, Maas JW, Bowden CL, Davis JM, Hanin I, Javaid J (1983): CSF and urinary biogenic amines and metabolites in depression and mania: A controlled univariate analysis. Arch Gen Psychiatry 40:999-1010
225. Kosten TR, Rounsaville BJ, Kosten TA, Merikangas K (1991): Gender differences in the specificity of alcoholism transmission among the relatives of opioid addicts. J Nerv Ment Dis 179:392-400
226. 1A autoreceptors of the dorsal and median raphe nuclei. J Pharmacol Exp Ther 269:1268-1279
227. Kreiss DS, Lucki I (1995): Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274(2):866-876
228. Kupfer DJ (1976): REM latency: A psychobiological marker for primary depressive disease. Biol Psychiatry 11:159-174
229. Lal H, Prather PL, Rezazadeh SM (1991): Anxiogenic behavior in rats during acute and protracted ethanol withdrawal: Reversal by buspirone. Alcohol 8:467-471
230. Lam RW, Zis AP, Grewal A, Delgado PL, Charney DS, Krystal JH (1996): Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. Arch Gen Psychiatry 53:41-44
231. 1A) receptor-mediated hypothermic response to ipsapirone in unipolar depression. Life Sci 46:1271-1277
232. 1A receptors in the hippocampus and the raphe area of rats treated with clonazepam. Prog Neuropsychopharmacol Biol Psychiatry 17:663-677
233. Lippa AS, Greenblatt EN, Pelham W (1977): The use of animal models for delineating the mechanisms of action of anxiolytic agents. In Hanin I, Usdin E (eds), Animal Models in Psychiatry and Neurology. New York, Pergamon Press, pp 279-292
234. Liskow BI, Goodwin DW (1987): Pharmacological treatment of alcohol intoxication, withdrawal and dependence: A critical review. J Stud Alcohol 48:356-370
235. Lloyd KG, Morselli PL (1987): Psychopharmacology of GABAergic drugs. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York, Raven Press, pp 183-195
236. Lloyd KG, Pichat P, Scatton B, Zivkovic B, Morselli PL, Bartholini G (1990): The psychopharmacology of GABA synapses: Update 1989. J Neural Transm Suppl 29:13-28
237. Lloyd KG, Thuret F, Pilc A (1985): Upregulation of gama-aminobutyric acid (GABA) B binding sites in rat frontal cortex: A common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther 235:191-199
238. Lloyd KG, Zivkovic B, Scatton B, Morselli PL, Bartholini G (1989): The GABAergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry 13:341-351
239. Loh EA, Roberts DCS (1990): Break points on a progressive ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. Psychopharmacology 101:262-266
240. Maas JW, Fawcett J, Dekirmenjian H (1968): 3-Methoxy-4-hydroxyphenylglycol (MHPG) excretion in depressive states: A pilot study. Arch Gen Psychiatry 19:129-134
241. Maas JW, Koslow SH, Davis J, Katz M, Frazer A, Bowden CL, Berman N, Gibbons R, Stokes P, Landis DH (1987): Catecholamine metabolism and disposition in healthy and depressed subjects. Arch Gen Psychiatry 44:337-344
242. Maggi A, U'Prichard DC, Enna SJ (1980): Differential effects of antidepressant treatment on brain monoaminergic receptors. Eur J Pharmacol 61:91-98
243. Maj J, Papp M, Skuza G, Bigajska K, Zazula M (1989a): The influence of repeated treatment with imipramine, (+)-and (-)-oxaprotiline on behavioural effects of dopamine D-1 and D-2 agonists. J Neural Transm 76:29-38
244. Maj J, Rogoz Z, Skuza G, Sowinska H (1989b): Antidepressants given repeatedly increase the behavioural effect of dopamine D-2 agonist. J Neural Transm 78:1-8
245. Maj J, Wedzony K, Klimek V (1987): Desipramine given repeatedly enhances behavioural effects of dopamine and d-amphetamine injected into the nucleus accumbens. Eur J Pharmacol 140:179-85
246. Maldonado R, Koob GF (1993): Destruction of the locus coeruleus decreases physical signs of opiate withdrawal. Brain Res 605(1):128-138
247. Maldonado R, Stinus L, Gold LH, Koob GF (1992): Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261:669-677
248. Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, Conrad DL, Wilson OB (1994): The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 115:180-184
249. Malin DH, Lake JR, Carter VA, Cunningham JS, Wilson OB (1993): Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 112:339-342
250. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB (1992): Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43:779-784
251. Malin DH, Lake JR, Payne MC, Short PE, Carter VA, Cunningham JS, Wilson OB (1996a): Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol Biochem Behav 53(1):81-85
252. Malin DH, Lake JR, Short PE, Blossmar JB, Lawless BA, Schopen CK, Sailer EE, Burgess K, Wilson OB (1996b): Nicotine abstinence syndrome precipitated by an analog of neuropeptide FF. Pharmacol Biochem Behav 54(3)581-585
253. Manier DH, Gillespie DD, Sanders-Bush E, Sulser F, (1987a): The serotonin/noradrenalin-link in brain. I. The role of noradrenaline and serotonin in the regulation of density and function of beta adrenoceptors and its alteration by desipramine. Naunyn-Schmiedebergs Arch Pharmacol 335:109-114
254. Manier DH, Gillespie DD, Steranka LR, Sulser F (1984): A pivotal role for serotonin (5HT) in the regulation of beta adrenoceptors by antidepressants: Reversibility of the action of parachlorophenylalanine by 5-hydroxytryptophan. Experientia 40:1223-1226
255. Manier DH, Gillespie DD, Sulser F (1987b): 5,7-Dihydroxytryptamine-induced lesions of serotonergic neurons and desipramine-induced down-regulation of cortical beta adrenoceptors: A re-evaluation. Biochem Pharmacol 36:3308-3310
256. 2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 43:954-959
257. Markou A, Hauger RL, Koob GF (1992): Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology 109:305-314
258. Markou A, Koob GF (1991): Postcocaine anhedonia: An animal model of cocaine withdrawal. Neuropsychopharmacology 4:17-26
259. Markou A, Koob GF (1992): Bromocriptine reverses the elevation in intracranial self-stimulation thresholds observed in a rat model of cocaine withdrawal. Neuropsychopharmacology 7:213-224
260. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF (1993): Animal models of drug craving. Psychopharmacology 112:163-182
261. Martin-Iverson MT, Leclere J-F, Fibiger HC (1983): Cholinergic-dopaminergic interactions and the mechanisms of action of antidepressants. Eur J Pharmacol 94:193-201
262. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB (1996): A double-blind placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 275(10):761-767
263. Mayeaux R (1990): Depression in the patient with Parkinson's disease. J Clin Psychiatry 51(Suppl 7):20-23
264. McBride WJ, Murphy JM, Lumeng L, Li T-K (1988): Effects of Ro 15-4513, fluoxetine and desipramine in the intake of ethanol, water and food by the alcohol-preferring (P) and -nonpreferring (NP) lines of rats. Pharmacol Biochem Behav 30:1045-1050
265. McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM (1996): Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. Arch Gen Psychiatry 53(3):232-240
266. McGrath PJ, Stewart JW, Quitkin FM, Wager S, Jenkins SW, Archibald DG, Stringfellow JC, Robinson DS (1994): Gepirone treatment of atypical depression: Preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 14(5):347-352
267. McGregor A, Lacosta S, Roberts DCS (1993): L-tryptophan decreases the breaking point under a progressive ratio schedule of intravenous cocaine reinforcement in the rat. Pharmacol Biochem Behav 44:651-655
268. McGregor A, Roberts DCS (1993): Dopaminergic antagonism within the nucleus accumbens or the amygdala produces differential effects on intravenous cocaine self-administration under fixed and progressive ratio schedules of reinforcement. Brain Res 624:245-252
269. McKeith IG, Marshall EF, Ferrier IN, Armstrong MM, Kennedy WN, Perry RH, Perry EK, Eccleston D (1987): 5-HT receptor binding in post-mortem brain from patients with affective disorder. J Affect Disord 13:67-74
270. McKinney WT (1988): Models of Mental Disorders. New York, Plenum Publishing Corporation
271. Menzaghi F, Howard RL, Heinrichs SC, Vale W, Rivier J, Koob GF (1994): Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 269(2):564-572
272. Merikangas KR, Prusoff BA, Weissman MM (1988): Parental concordance for affective disorders: Psychopathology in offspring. J Affect Disord 15:279-290
273. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF, Weiss F (1996): Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15(8):5439-5447
274. Mikkelsen JD, Woldbye D, Kragh J, Larsen PJ, Bolwig TG (1994): Electroconvulsive shocks increase the expression of neuropeptide Y (NPY) mRNA in the piriform cortex and the dentate gyrus. Mol Brain Res 23:317-322
275. Miller HL, Delgado PL, Salomon RM. Berman R, Krystal JH, Heninger GR, Charney DS (1996): Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 53:117-128
276. Mishra R, Janowsky A, Sulser F (1979): Subsensitivity of the norepinephrine receptor-coupled adenylate cyclase system in brain: Effects of nisoxetine versus fluoxetine. Eur J Pharmacol 60:379-382
277. Mishra R, Janowsky A, Sulser F (1980): Action of mianserin and zimelidine on the norepinephrine receptor coupled adenylate cyclase system in brain: Subsensitivity without reduction in beta-adrenergic receptor binding. Neuropharmacology 19:983-987
278. Mishra R, Sulser F (1978): Role of serotonin reuptake inhibition in the development of subsensitivity of the norepinephrine (NE) receptor coupled adenylate cyclase system. Commun Psychopharmacol 2:365-369
279. Moreau J-L, Scherschlicht R, Jenck F, Martin JR (1995): Chronic mild stress-induced anhedonia model of depression: Sleep abnormalities and curative effects of electroshock treatment. Behav Pharmacol 6:682-687
280. A receptor function and expression in brain. Alcohol 7:237-244
281. A receptor function and expression following chronic ethanol and barbiturate administration. Ann NY Acad Sci 625:496-507
282. Morselli PL, Boswsi L, Henry JF, Zarifian E, Bartholini G (1980): On the therapeutic action of SL 76002, a new GABA-mimetic agent. Brain Res Bull 5(Suppl 2):411-415
283. Muscat R, Papp M, Willner P (1992): Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 31:937-946
284. Muscat R, Sampson D, Willner P (1990): Dopaminergic mechanism of imipramine action in an animal model of depression. Biol Psychiatry 28:223-230
285. Myers JK, Weissman MM, Tischler GL, Holzer CE 3rd, Leaf PJ, Orvaschel H, Anthony JC, Boyd JH, Burke JD Jr, Kramer M, Stoltzman R (1984): Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry 41:959-967
286. Nader K, van der Kooy D (1996): Clonidine antagonizes the aversive effects of opiate withdrawal and the rewarding effects of morphine only in opiate withdrawn rats. Behav Neurosci 110(2):389-400
287. Nalepa I, Vetulani J (1993): Enhancement of the responsiveness of cortical adrenergic receptors by chronic administration of the 5-hydroxytryptamine uptake inhibitor citalopram. J Neurochem 60(6):2029-2035
288. Negus SS, Henriksen SJ, Mattox A, Pasternak GW, Portoghese PS, Takemori AE, Weinger MB, Koob GF (1993): Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats. J Pharmacol Exp Ther 265:1245-1252
289. Nelson DR, Pratt GD, Palmer KJ, Johnson AM, Bowery NG (1991): Effect of paroxetine, a selective 5-hydroxytryptamine uptake inhibitor, on beta-adrenoceptors in rat brain: Autoradiographic and functional studies. Neuropharmacology 30(6):607-616
290. Nelson DR, Thomas DR, Johnson AM (1989): Pharmacological effects of paroxetine after repeated administration to animals. Acta Psychiatr Scand (Suppl 350):21-23
291. Nemeroff CB, Bissette G, Akil H, Fink M (1991): Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: Corticotropin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158:59-63
292. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988): Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45:577-579
293. Nemeroff CB, Widerlov E, Bissette G, Waleus H, Karlsson T, Eklund K, Kilts CD, Loosen PT, Vale W (1984): Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226: 1342-1344
294. Nielsen NP, Cesana B, Zizolfi S, Ascalone V, Priore P, Morselli PL (1990): Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: A double-blind study versus clomipramine. Acta Psychiatr Scand 82:366-371
295. Nisell M, Nomikos GG, Svensson TH (1994a): Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 75(6):348-352
296. Nisell M, Nomikos GG, Svensson TH (1994b): Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16(1):36-44
297. Nisell M, Nomikos GG, Svensson TH (1995): Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 76:157-162
298. Nomikos GG, Zis AP, Damsma G, Fibiger HC (1991): Electroconvulsive shock produces large increases in the interstitial concentrations of dopamine in the rate striatum: An in vivo microdialysis study. Neuropsychopharmacology 4:65-69
299. Nunes EV, McGrath PJ, Quitkin FM, Ocepek-Welikson K, Stewart JW, Koenig T, Wager S, Klein DF (1995): Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 39(3):185-195
300. Nunes EV, McGrath PJ, Quitkin FM, Stewart JP, Harrison W, Tricamo E, Ocepek-Welikson K (1993): Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry 150:963-965
301. Overstreet DH (1993): The Flinders Sensitive Line rats: A genetic animal model of depression. Neurosci Biobehav Rev 17:51-68
302. Overstreet DH, Russell RW, Crocker AD, Schiller GD (1984): Selective breeding for differences in cholingeric function: Pre-and post-synaptic mechanisms involved in sensitivity to the anticholinesterase, DFP. Brain Res 294:327-332
303. Owens MJ, Vargas MA, Nemeroff CB (1993): The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: Implications for a role for CRF in the pathogenesis of anxiety disorders. J Psychiatr Res 27(supp 1):209-220
304. Palacios JM, Waeber C, Hoyer D, Mengod G (1990): Distribution of serotonin receptors. Ann NY Acad Sci 600:36-52
305. Palmer GC, Sulser F, Robison GA (1973): Effects of neurohumoral and adrenergic agents on cyclic AMP levels in various areas of the rat brain in vitro. Neuropharmacology 12:327-337
306. Palvimaki EP, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J (1994): Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology 115(4):543-546
307. 2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology 115: 441-146
308. Papp M, Muscat R, Willner P (1992): Additive effects of chronic treatment with antidepressant drugs and intermittent treatment with a dopamine agonist. Eur Neuropsychopharmacol 2:121-125
309. Parsons LH, Justice JR (1993): Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo micordialysis. Brain Res 606:195-199
310. Parsons LH, Koob GF, Weiss F (1995): Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 274:1182-1191
311. Parsons LH, Koob GF, Weiss F (1996): Serotonin-1B receptor stimulation enhances cocaine reinforcement, cocaine-induced increases in nucleus accumbens dopamine and cocaine-induced decreases in ventral tegmental area GABA. Neurosci Abstr 22:921
312. Parsons LH, Smith AD, Justice JB Jr (1991): Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 9:60-65
313. Paul SM (1988): Anxiety and depression: A common neurobiological substrate? J Clin Psychiatry 49(Suppl 10):13-16
314. Paul SM, Crews FT (1980): Rapid desensitization of cerebral cortical beta-adrenergic receptors induced by desmethylimipramine and phenoxybenzamine. Eur J Pharmacol 62:349-350
315. 2 receptors after antidepressant administration in the forced swim test and other chronic antidepressant drug treatment. J Pharmacol Exp Ther 246:956-962
316. Peltier R, Schenk S (1993): Effects of serotonergic manipulations on cocaine self-administration in rats. Psychopharmacology 110:390-394
317. Peroutka SJ, Snyder SH (1980): Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding sites. Science 210:88-90
318. Perry EK, Gibson PH, Blessed PH, Perry RH, Tomlinson BE (1977): Neurotransmitter abnormalities in senile dementia. Neurosci Lett 34:247-265
319. Pettit HO, Ettenberg A, Bloom FE, Koob GF (1984): Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology 84:167-173
320. Pettit HO, Justice JB Jr (1991): Effect of dose on cocaine self-administration behavior and dopamine levels in the nucleus accumbens. Brain Res 539:94-102
321. Petty F (1995): GABA and mood disorders: A brief review and hypothesis. J Affect Disord 34:275-281
322. Petty F, Davis LL, Kabel D, Kramer GL (1996): Serotonin dysfunction disorders: A behavioral neurochemistry perspective. J Clin Psychiatry 57(Suppl 8):11-16
323. Petty F, Kramer GL, Fulton M, Davis L, Rush AJ (1995a): Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biol Psychiatry 37:806-810
324. Petty F, Schlesser MA (1981): Plasma GABA in affective illness: A preliminary investigation. J Affect Disord 3:339-343
325. Petty F, Steinberg J, Kramer GL, Fulton M, Moeller FG (1993): Desipramine does not alter plasma GABA in patients with major depression. J Affect Disord 29:53-56
326. Petty F, Trivedi MH, Fulton M, Rush AJ (1995b): Benzodiazepines as antidepressants: Does GABA play a role in depression? Biol Psychiatry 38:578-591
327. Peyrin L, Pequignot JM, Chauplannaz G, Laurent B, Aimard G (1985): Sulfate and glucuronide conjugates of 3-methyoxy-4-hydroxyphenylglycol (MHPG) in urine of depressed patients: Central and peripheral influences. J Neural Transm 63:255-269
328. Pickens RW, Svikis DS, McGue M, Lykken DT, Heston LL, Clayton PJ (1991): Heterogeneity in the inheritance of alcoholism: A study of male and female twins. Arch Gen Psychiatry 48(1):19-28
329. Pilc A, Lloyd KG (1984): Chronic antidepressants and GABA "B" receptors: A GABA hypothesis of antidepressant drug action. Life Sci 35:2149-2154
330. Pilotto R, Singer G, Overstreet D (1984): Self-injection of diazepam in naive rats: Effects of dose, schedule and blockade of different receptors. Psychopharmacology 84:174-177
331. Pitts F, Winokur G (1966): Affective disorder: VII. Alcoholism and affective disorders. J Psychiatr Res 4:37-50
332. Porrino LJ, Dworkin SI, Smith JE (1991): Basal forebrain involvement in self-administration of drugs of abuse. Adv Exp Med Biol 295:339-351
333. Porrino LJ, Ritz MC, Goodman NL, Sharpe LG, Kuhar MJ, Goldberg SR (1989): Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats. Life Sci 45:1529-1535
334. Post RM, Ballenger JC, Hare TA, Goodwin FK, Lake CR, Jimerson DC, Bunney WE, Jr (1980): CSF GABA in normals and patients with affective disorder. Brain Res Bull 5(Suppl 2):755-759
335. Post RM, Gold P, Rubinow DR, Ballenger JC, Bunney WE, Goodwin FK (1982): Peptides in the cerebrospinal fluid of neuropsychiatric patients: An approach to central nervous system peptide function. Life Sci 31:1-15
336. Post RM, Gordon EK, Goodwin FK, Bunney WE Jr. (1973): Central norepinephrine metabolism in affective illness: MHPG in the cerebrospinal fluid. Science 179:1002-1003
337. Prather PL, Rezazadeh SM, Lal H (1991): Mianserin in the treatment of ethanol withdrawal in the rat: Prevention of behaviors indicative of anxiety. Psychopharmacol Bull 27:285-289
338. Rao U, Ryan ND, Birmaher B, Dahl RE, Williamson DE, Kaufman J, Rao R, Nelson B (1995): Unipolar depression in adolescents: Clinical outcome in adulthood. J Am Acad Child Adolesc Psychiatry 34:566-578
339. Rassnick S, D'Amico E, Riley E, Koob GF (1993a): GABA antagonist and benzodiazepine partial inverse agonist reduce motivated responding for ethanol. Alcohol Clin Exp Res 17:124-130
340. Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993b): Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605:25-32
341. Ratrray M, Singhvi S, Wu PY, Andrews N, File SE (1993): Benzodiazepines increase preprocholecystokinin messenger RNA levels in rat brain. Eur J Pharmacol 245: 193-196
342. 1A agonist gepirone in depressed patients. Biol Psychiatry 28:73-78
343. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990): Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiological Catchment Area (ECA) study. JAMA 264(19):2511-2518
344. Reich W, Earles F, Frankel O, Shayka JJ (1993): Psychopathology in children of alcoholics. J Am Acad Child Adolesc Psychiatry 32:995-1002
345. Reynolds CF, Kupfer DJ (1987): Sleep research in affective illness: State of the art circa 1987. Sleep 10:199-215
346. Richardson NR, Roberts DCS (1991): Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci 49:833-840
347. Richter RM, Merlo Pich E, Koob GF, Weiss F (1995): Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. Neurosci Lett 187:169-172
348. Richter RM, Weiss F (1997): In vivo CRF release in rat amygdala is increased during withdrawal after cocaine self-administration with unlimited access. Submitted.
349. Riemann D, Hohagen F, Krieger S, Gann H, Muller WE, Olbrich R, Wark H-J, Bohus M, Low H, Berger M (1994): Cholinergic REM induction test: Muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia. J Psychiatr Res 28:195-210
350. Rimon R, Kultalahti ER, Kalli A, Koskinen T, Lepola U, Naarala M, Tick E (1991): Alprazolam and oxazepam in the treatment of anxious out-patients with depressive symptoms: A double-blind multicenter study. Pharmacopsychiatry 24(3):81-84
351. Risner M. Jones BE (1976): Role of noradrenergic and dopaminergic processes in amphetamine self-administration. Pharmacol Biochem Behav 5:477-482
352. Ritz MC, Kuhar MJ (1989): Relationship between self-administration of amphetamine and monoamine receptors in brain: Comparison with cocaine. J Pharmacol Exp Ther 248(3):1010-1017
353. 3H] dihydroalprenolol. Mol Pharmacol 36:201-210
354. Riva MA, Creese I (1989b): Reevaluation of the regulation of beta-adrenergic receptor binding by desipramine treatment. Mol Pharmacol 36:211-218
355. Robbins AS (1993): Pharmacological approaches to smoking cessation. Am J Prev Med 9(1):31-33
356. Roberts AJ, Cole M, Koob GF (1996): Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol Clin Exp Res 20(7):1289-1298
357. Roberts DC, Corcoran ME, Fibiger HC (1977): On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behav 6(6): 615-620
358. Robins LN, Heizer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD, Regier DA (1984): Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949-958
359. Robins LN, Regier DA (eds) (1991): Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, The Free Press
360. 1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression. J Clin Pharmacol 10(Suppl 3):67S-76S
361. Robledo P, Koob GF (1993): Two discrete nucleus accumbens projection areas differentially mediate cocaine self-administration in the rat. Behav Brain Res 55:159-166
362. 1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15(4):349-360
363. Rose JE, Corrigall WA (1997): Nicotine self-administration in animals and humans: Similarities and differences. Psychopharmacology 130:28-40
364. Rosenberg PA, Li Y (1995): Adenylyl cyclase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by beta-adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebral cortex. Brain Res 692:227-232
365. Rossetti ZL, Hmaidan Y, Gessa GL (1992): Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221:227-234
366. Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F (1991a): Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 48:43-51
367. Rounsaville BJ, Dolinksy ZS, Babor TF, Meyer R (1987): Psychopathology as a predictor of treatment outcome in alcoholics. Arch Gen Psychiatry 44:505-513
368. Rounsaville BJ, Kosten TR, Weissman MM, Prusoff B, Pauls D, Anton SF, Merikangas K (1991b): Psychiatric disorders in relatives of probands with opiate addiction. Arch Gen Psychiatry 48:33-42
369. Rounsaville BJ, Weissman MM, Kleber H, Wilber C (1982): Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 39:161-168
370. Roy A, De Jong J, Linnoila M (1989): Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients: A 5-year follow-up study. Arch Gen Psychiatry 46:609-612
371. Roy A, De Jong J, Lamparski D, George T, Linnoila M (1991): Depression among alcoholics: Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry 48(5):428-432
372. Roy A, Linnoila M (1988): Suicidal behavior, impulsiveness and serotonin. Acta Psychiatr Scand 78:529-535
373. Rubinow DR (1986): Cerebrospinal fluid somatostatin and psychiatric illness. Biol Psychiatry 21:341-365
374. Rubinow DR, Davis CL, Post RM (1995): Somatostatin in the central nervous system. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 553-562
375. Rutter JJ, Gundlah C, Auerbach SB (1994): Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 171:183-186
376. Samson HH, Haraguchi M, Tolliver GA, Sadeghi KG (1989): Antagonism of ethanol-reinforced behavior by the benzodiazepine inverse agonists RO15-4513 and FG7142: Relationship to sucrose reinforcement. Pharmacol Biochem Behav 33:601-608
377. Samson HH, Tolliver GA, Pfeffer AO, Sadeghi KG, Mills FG (1987): Oral ethanol reinforcement in the rat: Effect of the partial inverse benzodiazepine agonist RO15-4513. Pharmacol Biochem Behav 27:517-519
378. 1C receptors in the choroid plexus. J Pharmacol Exp Ther 247:169-173
379. Sanders-Bush E, Breeding M, Knoth K, Tsutsumi M (1989): Sertraline-induced desensitization of serotonin 5HT-2 receptor transmembrane signaling system. Psychopharmacology 99:64-69
380. 2 binding sites after mianserin: Comparison of loss of sites and brain levels of drug. Eur J Pharmacol 133:199-204
381. Satel SL, Price LH, Palumbo JM, McDouble CJ, Krystal JH, Gawin F, Charney DS, Heninger GR, Kleber HD (1991): Clinical phenomenology and neurobiology of cocaine abstinence: A prospective inpatient study. Am J Psychiatry 148(12):1712-1716
382. Scatton B, Lloyd KG, Zivkovic B, Dennis T, Claustre Y, Dedek J, Arbilla S, Langer SZ, Bartholini G (1987): Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat. J Pharmacol Exp Ther 241:251-257
383. Scatton B, Zivkovic B, Dedek J, Lloyd KG, Constantinidis J, Tissot R, Bartholini G (1982): Gamma-aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J Pharmacol Exp Ther 220:678-688
384. Schatzberg AF, Schildkraut JJ (1995): Recent studies on norepinephrine systems in mood disorders. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 911-920
385. Schildkraut JJ (1965): The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122:509-522
386. Schildkraut JJ, Keeler BA, Papousek M, Hartmann E (1973): MHPG excretion in depressive disorders: Relation to clinical subtypes and desynchronized sleep. Science 181:762-764
387. Schmidt MJ, Thornberry JF (1977): Norepinephrine-stimulated cyclic AMP accumulation in brain slices in vitro after serotonin depletion or chronic administration of selective amine reuptake inhibitors. Arch Int Pharmacodyn Ther 299:42-51
388. Schuckit MA (1985): The clinical implications of primary diagnostic groups among alcoholics. Arch Gen Psychiatry 42(11):1043-1049
389. Schuckit MA, Smith TL (1996): An 8-year follow-up of 450 sons of alcoholic and control subjects. Arch Gen Psychiatry 53:202-210
390. Schuckit MA, Tipp JE, Bergman M, Reich W, Hesselbrock VM, Smith TL (1997): A comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am J Psychiatry 154:948-957
391. Sellers EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, Woody GE (1997): Alprazolam and benzodiazepine dependence. J Clin Psychiatry 54:64-75
392. Sepinwall J, Cook L (1978): Behavioral pharmacology of anti-anxiety drugs. In Iversen LL, Iversen SD, Snyder SH (eds), Handbook of Psychopharmacology, Vol 13. London, Plenum Press, pp 345-393
393. Shiromani PJ, Overstreet D, Levy D, Goodrich CA, Campbell SA, Gillin JC (1988): Increased REM sleep in rats selectively bred for cholinergic hyperactivity. Neuropsychopharmacology 1:127-133
394. Shopsin B, Friedman E, Gershon S (1976): Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 33:811-819
395. Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S (1975): Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1(2):239-249
396. Sitaram N, Moore AM, Gillin JC (1979): Scopolamine-induced muscarinic supersensitivity in normal man: Changes in sleep. Psychiatry Res 1:9-16
397. Skolnick P, Stalvey LP, Daly JW, Hoyler E, Davis JN (1978): Binding of alpha-and beta-adrenergic ligands to cerebral cortical membranes: Effect of 6-hydroxydopamine treatment and relationship to the responsiveness of cyclic AMP-generating systems in two rat strains. Eur J Pharmacol 47(2):201-210
398. Smialowska M, Legutko B (1991): Influence of imipramine on neuropeptide Y immunoreactivity in the rat brain. Neuroscience 41:767-771
399. Smith KA, Fairburn CG, Cowen PJ (1997): Relapse of depression after rapid depletion of tryptophan. The Lancet 349:915-919
400. Snyder SH, Peroutka SJ (1982): A possible role of serotonin receptors in antidepressant drug action. Pharmacopsychiatria 15:131-134
401. Spyraki C, Fibiger HC (1981): Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 74:195-206
402. Stahl S (1993): Mixed anxiety and depression: Clinical implications. J Clin Psychiatry 54(Suppl):33-38
403. 1A receptors and pharmacotherapy: Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 30(1):39-43
404. Stanley M, Mann JJ (1983): Increased serotonin-2 binding sites in the frontal cortex of suicide victims. Lancet 1:214-216
405. Stewart J, deWit H, Eikelboom R (1984): Role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants. Psychol Rev 91(2):251-268
406. Stewart BS, Lemaire GA, Roache TD, Meisch RA (1994): Establishing benzodiazepines as oral reinforcers: Midazolam and diazepam self-administration in rhesus monkeys. J Pharmacol Exp Ther 271(1):200-211
407. Stinus L, Le Moal M, Koob GF (1990): The nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37:767-773
408. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY (1997): Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 16:162-173
409. Stockmeier CA, Martino AM, Kellar KJ (1985): A strong influence of serotonin axons on beta-adrenergic receptors in rat brain. Science 230:323-325
410. Stolerman IP, Jarvis MJ (1995): The scientific case that nicotine is addictive. Psychopharmacology 117:2-10
411. Sugrue MF (1981): Current concepts of the mechanisms of action of antidepressant drugs. Pharmacol Ther 13:219-247
412. Sugrue MF (1983): Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning, Pharmacol Ther 21:1-33
413. Sulser F (1983a): Mode of action of antidepressant drugs. J Clin Psychiatry 44:14-20
414. Sulser F (1983b): Deamplification of noradrenergic signal transfer by antidepressants: A unified catecholamine-serotonin hypothesis of affective disorders. Psychopharmacol Bull 19(3):300-304
415. Sulser F, Vetulani J, Mobley PL (1978): Mode of action of antidepressant drugs. Biochem Pharmacol 27:257-261
416. Suzdak PD, Gianutsos G (1985): Parallel changes in the sensitivity of gamma-aminobutyric acid and noradrenergic receptors following chronic administration of antidepressant and GABAergic drugs: A possible role in affective disorders. Neuropharmacology 24:217-222
417. Swanson LW, Sawchenko PE, Rivier J, Vale WW (1983): Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: An immunohistochemical study. Neuroendocrinology 36:165-186
418. Szostak C, Finlay JM, Fibiger HC (1987): Intravenous self-administration of the short-acting benzodiazepine midazolam in the rat. Neuropharmacology 26:1673-1676
419. Tabakoff B, Hoffman PL (1992): Alcohol: Neurobiology. In Lowenstein JH, Ruiz P, Millman RB (eds), Substance Abuse: A Comprehensive Textbook. Baltimore, MD, Williams and Wilkins, pp 152-185
420. Taylor JR, Elsworth JD, Garcia EJ, Grant SJ, Roth RH, Redmond DE Jr (1988): Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. Psychopharmacology 96:121-134
421. Tella SR (1995): Effects of monoamine reuptake inhibitors on cocaine self-administration in rats. Pharmacol Biochem Behav 51(4):687-692
422. Titievsky J, Seco G, Barranco M, Kyle EM (1982): Doxepin as adjunctive therapy for depressed methadone maintenance patients: A double-blind study. J Clin Psychiatry 43:454-456
423. Toth E, Sershen H, Hashim A, Vizi ES, Lajtha A (1992): Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: Role of glutamic acid. Neurochem Res 17(3):265-271
424. Vaccarino FJ, Bloom FE, Koob GF (1985): Blockade of nucleus accumbens opiate receptors attenuates intravenous heroin reward in the rat. Psychopharmacology 86:37-42
425. van Praag HM (1986): Indoleamines in depression and suicide. Prog Brain Res 65:59-71
426. Vetulani J, Stawarz RJ, Dingell JV, Sulser F (1976): A possible common mechanism of action of antidepressant treatments. Reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn-Schmiedebergs Arch Pharmacol 293: 109-114
427. Vetulani J, Sulser F (1975): Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257:495-496
428. Wahlestedt C, Blendy JA, Kellar KJ, Heilig M, Widerlov E, Ekman R (1990): Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat. Brain Res 507:65-68
429. Wahlestedt C, Karoum F, Jaskiw G, Wyatt RJ, Larhammar D, Ekman R, Reis DJ (1991): Cocaine-induced reduction of brian neuropeptide Y synthesis dependent on medial prefrontal cortex. Proc Natl Acad Sci USA 88:2078-2082
430. Wang RY, Aghajanian GK (1980): Enhanced sensitivity of amygdaloid neurons to serotonin and norepinephrine after chronic antidepressant treatment. Commun Psychopharmacol 4:83-90
431. Weddington WW, Brown BS, Haertzen CA, Cone EJ, Dax EM, Herning RI, Michaelson BS (1990): Changes in mood, craving, and sleep during sort-term abstinence reported by male cocaine addicts. Arch Gen Psychiatry 47:861-868
432. Weiss F, Markou A, Lorang MT, Koob GF (1992): Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res 593:314-318
433. Weiss F, Parsons LH, Schulteis G, Hyytia P, Bloom FE, Koob GF (1996): Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J Neurosci 16(10):3474-3485
434. 1A receptors in rat brain following antidepressant drug treatment. Synapse 4:347-352
435. Wender PH, Kety SS, Rosenthal D, Schulsinger F, Ortmann J, Lunde I (1986): Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry 43:923-929
436. West R, Gossop M (1994): Overview: A comparison of withdrawal symptoms from different drug classes. Addiction 89:1483-1489
437. West RJ, Jarvis MJ, Russell MAH, Carruthers ME, Feyerabend C (1984): Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict 79:215-219
438. Widdowson PS, Ordway GA, Halaris AE (1992): Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 59:73-80
439. Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R (1988): Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22:69-79
440. Wiech NL, Ursillo RC (1980): Acceleration of desipramine-induced decrease of rat corticocerebral beta-adrenergic receptors by yohimbine, Commun Psychopharmacol 4:95-100
441. Wielosz M (1981): Increased sensitivity to dopaminergic agonists after repeated electroconvulsive shock (ECS) in rat. Neuropharmacology 20:941-945
442. Wikler A (1973): Dynamics of drug dependence: Implications of a conditioning theory for research and treatment. Arch Gen Psychiatry 28:611-616
443. Williams JB, Gibbon M, First MB, Spitzer RL, Davis M, Borus J, Howes MJ, Kane J, Pope HG Jr, Rounsaville BJ et al. (1992): The structured clinical interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry 49(8):630-636
444. Willner P (1984): The ability of antidepressant drugs to desensitize beta-receptors is inversely correlated with their clinical potency. J Affect Disord 7:53-58
445. Willner P (1985): Antidepressants and serotonergic neurotransmission: An integrative review. Psychopharmacology 85:387-404
446. Willner P (1995): Dopaminergic mechanisms in depression and mania. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 921-931
447. Willner P, Muscat R, Papp M, Sampson D (1991): Dopamine, depression and antidepressant drugs. In Willner P, Schell-Kruger J (eds), The Mesolimbic Dopamine System: From Motivation to Action. Chichester, UK, John Wiley and Sons, pp 387-410
448. Winokur G, Pitts F (1965): Affective disorder. VI. A family history study of the prevalences, sex differences and possible genetic factors. J Psychiatr Res 3:113-123
449. Wise RA, Newton P, Leeb K, Burnette B, Pocock D, Justice Jr JB (1995): Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology 120(1):10-20
450. Wittchen HU, Essau CA (1993): Comorbidity and mixed anxiety-depressive disorders: Is there epidemiologic evidence? J Clin Psychiatry 54(Suppl 1):9-15
451. Wolfe BB, Harden TK, Sporn JR, Molinoff PB (1978): Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther 207:446-457
452. Wong DT, Bymaster FP, Engleman EA (1995a): Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci 57(5):411-441
453. Wong DT, Bymaster FP, Engleman EA (1995b): Presynaptic regulation of extracellular serotonin concentrations in brain. In Takada A, Curzon G (eds), Serotonin in the Central Nervous System and Periphery. Elsevier Science BV, pp 3-13
454. Wong DT, Reid LR, Bymaster FP, Threlkeld PG (1985): Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptors. J Neural Transm 64(3-4):251-269
455. Wonnacott S (1990): The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 11:216-219
456. Woody GE, O'Brien CP, McLellan AT, Marcovici M, Evans BD (1982): The use of antidepressants with methadone in depressed maintenance patients. Ann NY Acad Sci 398:120-127
457. Woody GE, O'Brien CP, Rickels K (1975): Depression and anxiety in heroin addicts: A placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry 132:447-450
458. Woolverton WL (1987): Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys. Pharmacol Biochem Behav 26(4): 835-839
459. Yanagita T, Takahashi S (1973): Dependence liability of several sedative-hypnotic agents evaluated in monkeys. J Pharmacol Exp Ther 185:307-316
460. 2 receptor changes in major depression. Biol Psychiatry 27:489-496
461. Yeomans JS (1995): Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12(1):3-16
462. Yokel RA, Wise RA (1976): Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology 48:311-318
463. Young SN, Smith SE, Pihl RO, Ervin FR (1985): Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87:173-177
464. Yu O, Chiu TH, Rosenberg HC (1988): Modulation of GABA-gated chloride ion flux in rat brain by acute and chronic benzodiazepine administration. J Pharmacol Exp Ther 246:107-113
465. Zakusov VV, Ostrovskaya RU, Kozhechkin SN, Markovich VV, Molodavkin GM, Voronina TA (1977): Further evidence for GABAergic mechanisms in the action of benzodiazepines. Arch Int Pharmacody Ther 229:313-326
466. Ziedonis DM, Kosten TR (1991): Depression as a prognostic factor for pharmacological treatment of cocaine dependence. Psychopharmacol Bull 27(3):337-343